Yeast-based high-throughput screens for discovery of kinase inhibitors for neglected diseases.
Adv Protein Chem Struct Biol
; 124: 275-309, 2021.
Article
in English
| MEDLINE | ID: covidwho-1375869
ABSTRACT
The discovery and development of a new drug is a complex, time consuming and costly process that typically takes over 10 years and costs around 1 billion dollars from bench to market. This scenario makes the discovery of novel drugs targeting neglected tropical diseases (NTDs), which afflict in particular people in low-income countries, prohibitive. Despite the intensive use of High-Throughput Screening (HTS) in the past decades, the speed with which new drugs come to the market has remained constant, generating doubts about the efficacy of this approach. Here we review a few of the yeast-based high-throughput approaches that can work synergistically with parasite-based, in vitro, or in silico methods to identify and optimize novel antiparasitic compounds. These yeast-based methods range from HTP screens to identify novel hits against promising parasite kinase targets to the identification of potential antiparasitic kinase inhibitors extracted from databases of yeast chemical genetic screens.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Protein Kinases
/
Saccharomyces cerevisiae
/
Protein Kinase Inhibitors
/
Drug Discovery
/
Neglected Diseases
Type of study:
Prognostic study
Topics:
Traditional medicine
Limits:
Humans
Language:
English
Journal:
Adv Protein Chem Struct Biol
Journal subject:
Biology
/
Biochemistry
Year:
2021
Document Type:
Article
Affiliation country:
Bs.apcsb.2020.09.007
Similar
MEDLINE
...
LILACS
LIS